EA201992226A1 - Агонисты npra, композиции и их использование - Google Patents
Агонисты npra, композиции и их использованиеInfo
- Publication number
- EA201992226A1 EA201992226A1 EA201992226A EA201992226A EA201992226A1 EA 201992226 A1 EA201992226 A1 EA 201992226A1 EA 201992226 A EA201992226 A EA 201992226A EA 201992226 A EA201992226 A EA 201992226A EA 201992226 A1 EA201992226 A1 EA 201992226A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fatty acyl
- natriuretic peptide
- terminus
- integer
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 title 1
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- JSOQIZDOEIKRLY-UHFFFAOYSA-N n-propylnitrous amide Chemical compound CCCNN=O JSOQIZDOEIKRLY-UHFFFAOYSA-N 0.000 title 1
- 108020001621 Natriuretic Peptide Proteins 0.000 abstract 4
- 102000004571 Natriuretic peptide Human genes 0.000 abstract 4
- 125000001924 fatty-acyl group Chemical group 0.000 abstract 4
- 239000000692 natriuretic peptide Substances 0.000 abstract 4
- 239000004475 Arginine Chemical group 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000009723 vascular congestion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475147P | 2017-03-22 | 2017-03-22 | |
| PCT/US2018/023491 WO2018175534A1 (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992226A1 true EA201992226A1 (ru) | 2020-02-12 |
Family
ID=63585777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992226A EA201992226A1 (ru) | 2017-03-22 | 2018-03-21 | Агонисты npra, композиции и их использование |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200017567A1 (https=) |
| EP (1) | EP3601314A4 (https=) |
| JP (2) | JP7126270B2 (https=) |
| KR (1) | KR102714599B1 (https=) |
| CN (1) | CN110603260B (https=) |
| AU (2) | AU2018239352A1 (https=) |
| BR (1) | BR112019019720A2 (https=) |
| CA (1) | CA3056433A1 (https=) |
| EA (1) | EA201992226A1 (https=) |
| IL (1) | IL269388B2 (https=) |
| MX (1) | MX2019010960A (https=) |
| MY (1) | MY201165A (https=) |
| PH (1) | PH12019550163A1 (https=) |
| SG (1) | SG11201908580XA (https=) |
| WO (1) | WO2018175534A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020236688A1 (en) | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| EP3972589B1 (en) * | 2019-05-22 | 2024-07-03 | Merck Sharp & Dohme LLC | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20230241164A1 (en) * | 2020-06-12 | 2023-08-03 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer |
| IL298980A (en) * | 2020-06-12 | 2023-02-01 | Pharmain Corp | C-type natriuretic peptides and methods thereof in treating acute lung injury |
| IL320341A (en) * | 2022-10-21 | 2025-06-01 | Lilly Co Eli | Long-acting natriuretic peptides and uses thereof |
| EP4612167A1 (en) * | 2022-11-02 | 2025-09-10 | Novo Nordisk A/S | Cnp compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985722A (en) * | 1973-12-12 | 1976-10-12 | Ajinomoto Co., Inc. | Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins |
| FR2687156B1 (fr) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
| CN1062311C (zh) * | 1996-12-27 | 2001-02-21 | 中国医学科学院基础医学研究所 | 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用 |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| AU2003297583B2 (en) * | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US8933197B2 (en) * | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| CN101809029B (zh) * | 2008-05-23 | 2016-06-15 | 第一三共株式会社 | 具有延长目标肽的血浆半衰期作用的肽 |
| ES2608457T3 (es) * | 2009-05-20 | 2017-04-11 | Biomarin Pharmaceutical Inc. | Variantes de péptido natriurético de tipo C |
| JP6055779B2 (ja) * | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| CN103402534B (zh) * | 2011-02-23 | 2016-10-12 | 麦德林制药私人有限公司 | 用于治疗充血性心力衰竭的治疗方法 |
| EP2678028A2 (en) * | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
-
2018
- 2018-03-21 EA EA201992226A patent/EA201992226A1/ru unknown
- 2018-03-21 BR BR112019019720A patent/BR112019019720A2/pt unknown
- 2018-03-21 EP EP18771099.1A patent/EP3601314A4/en active Pending
- 2018-03-21 CA CA3056433A patent/CA3056433A1/en active Pending
- 2018-03-21 SG SG11201908580X patent/SG11201908580XA/en unknown
- 2018-03-21 IL IL269388A patent/IL269388B2/en unknown
- 2018-03-21 AU AU2018239352A patent/AU2018239352A1/en not_active Abandoned
- 2018-03-21 MY MYPI2019005393A patent/MY201165A/en unknown
- 2018-03-21 CN CN201880028963.9A patent/CN110603260B/zh active Active
- 2018-03-21 JP JP2019551608A patent/JP7126270B2/ja active Active
- 2018-03-21 MX MX2019010960A patent/MX2019010960A/es unknown
- 2018-03-21 KR KR1020197031122A patent/KR102714599B1/ko active Active
- 2018-03-21 WO PCT/US2018/023491 patent/WO2018175534A1/en not_active Ceased
-
2019
- 2019-09-12 PH PH12019550163A patent/PH12019550163A1/en unknown
- 2019-09-20 US US16/577,947 patent/US20200017567A1/en active Pending
-
2022
- 2022-04-22 JP JP2022070710A patent/JP2022090049A/ja not_active Withdrawn
-
2025
- 2025-02-21 AU AU2025201270A patent/AU2025201270A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL269388B1 (en) | 2024-11-01 |
| EP3601314A1 (en) | 2020-02-05 |
| MX2019010960A (es) | 2020-01-20 |
| JP2022090049A (ja) | 2022-06-16 |
| CN110603260B (zh) | 2023-11-07 |
| EP3601314A4 (en) | 2021-01-13 |
| KR20190133201A (ko) | 2019-12-02 |
| AU2018239352A1 (en) | 2019-10-10 |
| CN110603260A (zh) | 2019-12-20 |
| SG11201908580XA (en) | 2019-10-30 |
| JP7126270B2 (ja) | 2022-08-26 |
| WO2018175534A1 (en) | 2018-09-27 |
| KR102714599B1 (ko) | 2024-10-07 |
| AU2025201270A1 (en) | 2025-03-13 |
| IL269388A (en) | 2019-11-28 |
| JP2020511494A (ja) | 2020-04-16 |
| MY201165A (en) | 2024-02-08 |
| PH12019550163A1 (en) | 2020-06-08 |
| US20200017567A1 (en) | 2020-01-16 |
| CA3056433A1 (en) | 2018-09-27 |
| BR112019019720A2 (pt) | 2020-04-28 |
| IL269388B2 (en) | 2025-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992226A1 (ru) | Агонисты npra, композиции и их использование | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| EA200901459A1 (ru) | Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства | |
| MA41778A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| EA200900373A1 (ru) | Реконструированные сурфактанты, обладающие улучшенными свойствами | |
| CY1116011T1 (el) | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει | |
| EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
| MX384800B (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| JP2018505146A5 (https=) | ||
| JP2016512214A5 (https=) | ||
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| EA201691883A1 (ru) | Жидкая композиция, содержащая соединение, нейтрализующее gm-csf | |
| BR112018072034A2 (pt) | compostos mic-1 e usos dos mesmos | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| MX2021003810A (es) | Composiciones terapeuticas. | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| ZA202005325B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| CU24609B1 (es) | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic | |
| MX378591B (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MX2025001402A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas | |
| MX2022011071A (es) | Composiciones que mejoran la estabilidad del poxvirus. | |
| EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз | |
| PE20220566A1 (es) | ANTICUERPOS DE UNION A VISTA A pH ACIDO |